Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 962

Showing 1-25 of 962 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1127
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
Gracia Fahed, Laurence Aoun, Morgan Bou Zerdan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 786-786
Open Access | Times Cited: 891
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 683
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 669
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey, Rachel L. Batterham, Meena Bhatta, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2083-2091
Open Access | Times Cited: 405
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao, Minghe Wang, Zhitong Wen, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 247
Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021
Dan J. Stein, Hazim Ababneh, Yohannes Habtegiorgis Abate, et al.
The Lancet (2024) Vol. 403, Iss. 10440, pp. 2204-2256
Open Access | Times Cited: 231
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 215
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 215
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx, Mansoor Husain, Michael Lehrke, et al.
Circulation (2022) Vol. 146, Iss. 24, pp. 1882-1894
Open Access | Times Cited: 209
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 203
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton, Thomas Blevins, Lisa Connery, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 10, pp. 877-888
Closed Access | Times Cited: 198
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 175
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 156
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Giulia Bendotti, Laura Montefusco, Maria Elena Lunati, et al.
Pharmacological Research (2022) Vol. 182, pp. 106320-106320
Closed Access | Times Cited: 147
Metabolic Messengers: glucagon-like peptide 1
Fiona M. Gribble, Frank Reimann
Nature Metabolism (2021) Vol. 3, Iss. 2, pp. 142-148
Closed Access | Times Cited: 140
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 9, pp. 623-633
Closed Access | Times Cited: 134
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
Matthias von Herrath, Stephen C. Bain, Bruce W. Bode, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 4, pp. 212-224
Open Access | Times Cited: 124
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 124
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart, Michael Wagner, Ralf Elvert, et al.
Cell Metabolism (2021) Vol. 34, Iss. 1, pp. 59-74.e10
Open Access | Times Cited: 121
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
Sean Wharton, Melanie J. Davies, Dror Dicker, et al.
Postgraduate Medicine (2021) Vol. 134, Iss. 1, pp. 14-19
Open Access | Times Cited: 109
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 103
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Juan José Gorgojo Martínez, Pedro Mezquita‐Raya, Juana Carretero Gómez, et al.
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 145-145
Open Access | Times Cited: 95
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
Lulu Liu, Jia Chen, Lei Wang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 93
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 78
Page 1 - Next Page

Scroll to top